HSPB8 and prostate cancer: Conversely, other studies showed that HSPB8 is downregulated in leukemia and lymphoma [61], glioblastoma [62, 63], hepatocarcinoma [64, 65], prostate cancer [39, 66, 67], melanoma [39, 40, 68–70] and its upregulation contributes to induce cell death and chemosensitivity generating an overall antitumoral effect.